Treating Partially Responsive Depression (PRD) as an unmet medical need ANEUROTECH is developing its late stage Phase III drug ANT01 in Partial Responsive Depression (PRD). ANT01 is an once daily, orally-administered small molecule to attack Subjective Cognitive Decline and Potentiate Initial Antidepressant Therapies. This established drug acts uniquely as a combined High Selective Serotonin 2A... Read more »